Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 8/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | CTSV | O60911 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753451 | 0.93 | CDK2 (0.41) | HPGDSCTSLCTSSCDK2HCK | |
| SCHEMBL6752379 | 0.91 | HPGDS (0.48) | HPGDSCTSLCTSSCTSBCDK2 | |
| SCHEMBL6752296 | 0.86 | CTSK (0.43) | CTSLCTSSCTSBHCKNR2C2 | |
| SCHEMBL6698609 | 0.84 | HPGDS (0.37) | HPGDSCTSLCTSSCTSVCTSB | |
| SCHEMBL6752373 | 0.83 | HPGDS (0.49) | HPGDSCTSLCTSSCTSBCDK2 | |
| SCHEMBL6747828 | 0.82 | CTSL (0.47) | HPGDSCTSLCTSSCTSVCTSB | |
| SCHEMBL6753477 | 0.81 | HPGDS (0.39) | HPGDSCTSLCTSSCTSVCTSB | |
| SCHEMBL6752287 | 0.81 | HPGDS (0.38) | HPGDSCTSLCTSSCTSVCTSB | |
| SCHEMBL6752457 | 0.80 | HPGDS (0.39) | HPGDSCTSLCTSSCTSVCTSB | |
| SCHEMBL6752286 | 0.80 | CTSL (0.51) | HPGDSCTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362042-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | HPGDS 1248/4885CTSL 23/4885CTSS 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.